BAIT

TP53

BCC7, LFS1, P53, TRP53
tumor protein p53
GO Process (61)
GO Function (25)
GO Component (14)

Gene Ontology Biological Process

Homo sapiens

Negative Genetic

Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.

Publication

Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.

Liu C, Banister CE, Buckhaults PJ

TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA-approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineered TP53 deletion by genome editing. We identified 27 cancer therapeutic drugs for which TP53 mutations conferred resistance; ... [more]

Cancer Res Dec. 01, 2018; 79(9);2392-2403 [Pubmed: 30862715]

Throughput

  • Low Throughput

Additional Notes

  • CRISPR GI screen
  • Cell Line: hESC
  • Experimental Setup: Drug Exposure: Cisplatin CHEBI:27899
  • GIST: Mono-phenotypic suppressing genetic interaction
  • KO of hit genes re-sensitizes TP53 KO cells to cisplatin
  • Library: GeckoV2
  • Significance Threshold: p<0.01

Related interactions

InteractionExperimental Evidence CodeDatasetThroughputScoreCurated ByNotes
DYRK2 TP53
Proximity Label-MS
Proximity Label-MS

An interaction is inferred when a bait-enzyme fusion protein selectively modifies a vicinal protein with a diffusible reactive product, followed by affinity capture of the modified protein and identification by mass spectrometric methods.

High-BioGRID
-

Curated By

  • BioGRID